Here you find current and comprehensive information about Good Manufacturing Practice. Whether mobile phone, tablet or laptop - with the GMP:Blog you stay up to date no matter where you are!
Read the information that is important to you!
This is how it works: Use the drop-down fields to filter the information type, your subject area and the year of publication. You would like to decide even faster which type of information to be displayed to you? Then simply click on the graphics!
8 min. reading time | by Thomas Peither
A CAPA system should be understood as an important element of the pharmaceutical quality system and implemented uniformly throughout the company or group. In principle, it can be implemented in two different ways: as an autonomous or as an integrated system.
5 min. reading time |
From the start of the project to the release of the technical design: Risk analysis is a constant companion.
Risk analyses can or must be carried out at different points in time within the process of procurement and qualification. Here is a brief outline of the phases of risk analyses in project implementation.
7 min. reading time | by Stephanie Blum, PhD
Based on the risk assessment documented in the excipient dossier and the risk profile of the excipient, the risk team defines the necessary GMP requirements in the next step.
7 min. reading time | by Felix Kern, PhD and Liwa Schneider
Deviation management plays an increasingly important role in the collection and review of KPIs (Key Performance Indicators) for pharmaceutical production and quality processes. Tracking the cause of deviations in particular provides information on how stable the respective processes are, where there are gaps and where countermeasures need to be taken with corrective and preventive actions (CAPAs).
8 min. reading time | by Sabine Paris, PhD
"Contaminants in medicinal products – focus on nitrosamines" was the title of an online training course organised by the German FORUM Institute on 12 November 2021. Four renowned experts from the authorities, industry and consulting shed light on all aspects of nitrosamines that play a role in the life cycle of a medicinal product:
8 min. reading time | by Simone Ferrante
When materials or products are delivered, their quality is assessed. Therefore, this work step should be carried out by experienced and particularly reliable employees.
7 min. reading time | by Doris Borchert, PhD
The 27th PTS GMP Conference took place face-to-face and in parallel digitally from 30.11. to 01.12.2021 in Mainz, Germany. The hybrid event was broadcast live from the Atrium Hotel in Mainz, where most of the speakers were present in person.
The presentation by Rico Schulze, Saxon State Ministry for Social Affairs and Social Cohesion, on the revision status and publication of Annex 1 to the EU GMP Guideline was particularly eagerly awaited.
13 min. reading time | shortened version
From a regulatory perspective, the year 2021 had plenty in store. Parallel to the omnipresent COVID-19 pandemic, the authorities around the world managed to finalize draft documents that became “sideshows” while the pandemic took centre stage. What topics kept the GMP professionals on their toes?
8 min. reading time |
The life cycle of an equipment begins with initial qualification and ends with decommissioning. Once a qualification status has been achieved, it must be guaranteed over the entire life cycle until the equipment is decommissioned. This is ensured by regular calibration, maintenance, effective change management and periodic review.
6 min. reading time | by Christine Oechslein, PhD and Cornelia Wawretschek
For almost all purposes in the GMP sector, it is mandatory to use original data and documents or only true copies thereof. This requirement also forms part of the ALCOA principle. Since it is only possible in a few cases in operational practice to work with the sole original document, the question arises as to what requirements are to be placed on the requisite true copies (see definition in Figure 15.B-6). Figure 15.B-7 compares different types of copies with the concept of original data.
7 min. reading time | by Stephanie Blum, PhD
If a new service or material is required, the competent department first checks whether this service or material can be obtained from an already qualified supplier. If this is the case, the department initiates a follow-up qualification. Otherwise, the identification and pre-selection of potential new suppliers is carried out by the department itself.
8 min. reading time | by Thomas Trantow, PhD
8 min. reading time | by Simone Ferrante
In Europe, companies with a wholesale distribution authorisation, the management must appoint a responsible person who is responsible for the introduction and implementation of a quality management system and compliance with the GDP rules.
6 min. reading time | by Harald Flechl
Beginning from the definition of the User Requirements Specification (URS) the planning phase is subdivided into four stages:
5 min. reading time | by Felix Tobias Kern, PhD and Liwa Schneider
The GMP-compliant and timely management of deviations is very often addressed in audits. One reason for this is that deviations reveal gaps in the defined quality systems or indicate that they have not been set up correctly.
7 min. reading time | by Norbert Waldöfner, PhD
Figure 20.F-24 provides an overview of the GMP deficiencies that, in the author's experience, are frequently encountered during audits of active substance manufacturers.
6 min. reading time | by Sabine Paris, PhD
The PDA/FDA Joint Regulatory Conference, which is now in its 30th year, took place as a virtual event from September 27 – September 29. The Conference focused on the role of effective quality systems in ensuring an ongoing state of control throughout the product lifecycle by vigilantly managing risks to manufacturing and quality.
7 min. reading time | by André Deister, Sabine Mendel
The supplier of the packaging materials plays an important role when pharmaceutical packaging materials undergo testing. Because of the numerous materials involved, the complexity of the manufacturing process and the extremely specific test parameters, many of the packaging material tests are carried out at the supplier.
7 min. reading time | by Sabine Paris, PhD
The PDA/FDA Joint Regulatory Conference, which is now in its 30th year, took place as a virtual event from September 27 – September 29. The Conference focused on the role of effective quality systems in ensuring an ongoing state of control throughout the product lifecycle by vigilantly managing risks to manufacturing and quality.
7 min. reading time | by Felix Tobias Kern, PhD, and Fritz Röder
Defect evaluation lists and defect pattern libraries are popular GMP documents that have been used for more than 45 years. They serve as a rationale for the quality assessment of individual batches and set quality standards for the manufacture and testing of pharmaceutical products.
7 min. reading time |
A GMP compliant and successful process validation is only possible when a 'robust' 1 pharmaceutical development of the medicinal product has been performed, regardless of which development methods are applied.
12 min. reading time | by Harald Flechl
We operate a laminar flow above an injection moulding machine in a cleanroom, GMP Grade C (ISO 8 in operation, ISO 7/at rest). The laminar flow achieves ISO class 5 within the cleanroom area.
8 min. reading time | by Markus Roemer, Siegfried Schmitt, PhD
The written contract on the outsourced activities can take the form of an internal service agreement or an external service agreement. In both cases, it is used to describe.
7 min. reading time | by Heike Meichsner, Olaf Mundszinger, PhD, Susanne Schweizer
The registration batches correspond as nearly as possible to the later commercial batches in the marketing phase with regard to the equipment, starting materials and manufacturing processes used.
8 min. reading time | by Richard Denk
Isolators are used in the handling of toxic and highly potent substances and in the production of sterile products.
9 min. reading time | by Stephanie Blum
In addition to the preceding general statements on the PQS, Chapter 1 of the EU GMP Guidelines contains specific information on GMP for medicinal products and quality control.
9 min. reading time | by Thomas Peither
The inspection is carried out in the front office and prepared in the back office. The preparation room is used to train and instruct staff.
11 min. reading time | by Thomas Peither
A definition of the term “qualification master plan (QMP)“ is not to be found in the GMP guidelines, only the term “validation master plan (VMP)”, which serves as a parent document.
9 min. reading time | by Dennis Sandkühler
On the basis of the process-related requirements set out in the specifications, ISPE GAMP® 5 provides for a process risk analysis to identify risks relating to patient safety, product quality, data integrity and compliance requirements.
9 min. reading time | by Lea Joos
During a tour of the production area, it was discovered at several points that the rooms were not sufficiently maintained:
7 min. reading time | by Stephanie Blum
With this e-learning course you can get familiar with the topic of Good Distribution Practice (GDP)!
10 min. reading time | by Christian Gausepohl
When selecting balances, technical aspects such as resolution, precision and weighing range must be taken into account, as must special design features.
7 min. reading time | by Harald Flechl
The design qualification process may vary depending on the project and the client's requirements and may be carried out in two or three design phases.
10 min. reading time | by Chistian Gausepohl
The transfer of a product to a contract manufacturer can be divided into different phases.
15 min. reading time | by Ulrich Kissel and David Cockburn
Social distancing posed an interesting question for the Qualified Person (QP) in the early days of the COVID-19 pandemic:
7 min. reading time | by Christian Gausepohl
Most companies have established different categories (qualification status) for the suppliers of starting materials and packaging materials they use.
8 min. reading time | by Thomas Peither
Were you able to follow the PDA Annual Meeting of the Parenteral Drug Association this year? Or were you like many others who spent the whole day with web meetings and have no time or mood for more online conferences?
4 min. reading time | by Michael Hiob and Sabine Paris,PhD
A referral is a procedure used to resolve concerns over the safety, efficacy or quality of a medicinal product (or a class of medicines). In a referral, the EMA is requested to conduct a scientific assessment of the products in question on behalf of the European Union (EU).
The time has come, the curtain goes up! Now your brand-new online journal is launched.
Let the newly designed GMP:Blog support you in the work with GMP.
5 min. reading time | by Roland Kleissendorf
A correctly formulated packaging material specification provides a comprehensive description of the packaging material and serves as a guideline for the respective packaging materials supplier.
8 min. reading time | by Sabine Paris
In 2015, with the revision of Chapters 3 and 5 and Annex 15 of the EU GMP Guide and with the publication of the EMA PDE Guideline a paradigm shift took place in establishing limit values for the validation of cleaning processes.
18 min. reading time
Today’s feature focuses on GMP risk analysis. It is an excerpt from the E-Learning GMP:READY – GMP for Engineers. GMP:READY provides knowledge for the planning, qualification and maintenance of the pharmaceutical equipment and facilities.
5 min. reading time | by Markus Veit
This chapter deals with the practical aspects of implementing the European requirements for data integrity.
12 min. reading time | by Dr. Sabine Paris
Time specifications for the start of production (preparation from 8:30) and for the end of production (15:30) were entered in the batch documentation.
11 min. reading time | by Sabine Paris
For all of us, the year 2020 turned out quite differently than we had ever imagined. People everywhere are struggling with new challenges. The GMP world was not spared, either. To name just a few: inspections were carried out remotely to a large extent and many regulations remained in draft form for the time being.
8 min. reading time | by Harald Flechl
Over the past several years, wall and ceiling systems have become the established state of the art in finishing technology. The numerous manufacturers of such systems also offer solutions that are suitable for fire zones and large, high rooms – such as warehouse storage rooms.
12 min. reading time | by Tim Sandle
Controlling water quality in pharmaceutical facilities requires an assessment of chemical and microbial risks. Of foremost concern is water-for-injections (WFI). This grade of water can be prepared using either reverse osmosis or by distillation.
10 min. reading time | by Doris Borchert and Christian Gausepohl
To err is human - and is only too willingly used as the most probable cause for deviations of all kinds. It is also temptingly easy to look for the cause of error in individual (mis)behaviour.
10 min. reading time | by Paulino Alonso
ICH Q3D 'Guideline for Elemental Impurities' applies to finished drug products. It provides the basis for an adequate control of elemental impurities (generally referred as 'heavy metals' or 'metallic impurities'). The publication of this guideline has brought several consequences:
10 min. reading time
Every week we publish GMP related questions which you might have asked yourself before. You get short and precise answers, links and working material to the corresponding chapters in the GMP Compliance Adviser.
12 min. reading time | by Doris Borchert
There is a first time for everything - in this case for the digital format of the GMP Conference, which PTS Training Service organised for the 26th time on 1 December 2020.
10 min. reading time | by Richard Denk
The literal meaning of containment is “holding together” or in its common sense “limiting expansion”. In the active ingredient, pharmaceutical and biopharmaceutical industries it is understood to mean the enclosure of a production process or a dangerous location.
9 min. reading time | by Felix Michler
The demands on manufacturers in the pharmaceutical industry are constantly increasing. Global competition and the international production and supply of raw materials and active ingredients increase the complexity of supply chains.
5 min. reading time | by Thomas Peither
In September 2020 the series of virtual autumn conferences of PDA and ISPE started. We were present and pick out some excellent sessions with this LOGFILE feature.
6 min. reading time | by Rainer Gnibl
Excerpt from the GMP Compliance Adviser Chapter 14.J and the GMP Series e-book EU-Compliant Batch Release of Medicinal Products
5 min. reading time | by Lea Joos
During the cleaning validation, the PDE values of the active ingredients were determined in order to implement the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities.
3 min. reading time
Is there a normative source for the fact that the reviewer of a document cannot be the same person who prepared it?
5 min. reading time | by Felix Tobias Kern and Liwa Schneider
The correct and consistent classification of deviations into the categories Minor, Major and Critical is a constant challenge for pharmaceutical manufacturers. A systematic specification is a prerequisite for the elimination of subjective components of the classifying QA function and the QPs.
6 min. reading time | by Christoph Frick
There is no legal, ecological or pharmaceutical reason why a preparation should be heated from 12 °C (the outside temperature), for example, to a constant temperature of 20 °C (i.e. the mean of 15–25 °C) and stored at this temperature.
13 min. reading time | by Axel Radke
Research, development and production of a medicinal product are usually in the hands of the marketing authorization holder (MAH). These processes are therefore subject to the direct supervision and control of the MAH.
8 min. reading time | by Hedley Rees
Not for the first time, pharma supply-chains have become the subject of global debate among key stakeholders, but for the wrong reasons.
5 min. reading time | by Mark Tucker
Issue identification is the most critical part of the process and relies on a team of people with high operational and GMP knowledge. All operational and quality areas should be represented and assessed.
8 min. reading time | by Christine Oechslein
In Part I, Paragraph 2.11 of the EU GMP Guidelines, it is required that "approved training programmes should be available" in GMP-liable establishments.
7 min. reading time | by Sabine Paris
For almost 30 years now, the PDA/FDA Joint Regulatory Conference has been taking place once a year. From 14 to 16 September 2020 it was a virtual-only event for the first time. The title of the conference was "The Future Is Now: Effective Quality Management and Robust Manufacturing".
5 min. reading time | by Crystal Booth
When selecting the number of sites to be sampled, the author recommends utilizing established guidelines. For example, ISO 14644-1:2015 contains a table used to establish the number of nonviable (total) particulate samples required based on the size of the room to be monitored.
5 min. reading time | by Harald Flechl / Doris Borchert (editorial editing)
In cleanrooms, it is necessary to create a clear demarcation to adjacent, less clean areas. Since the beginning of clean room technology, airlocks have established themselves as an effective means of separating rooms.
5 min. reading time | by Lea Joos
In the case of the deviation inspected, it was found that the batch number, which had to be manually transferred to the product before production started, was not correctly transferred to the product. The cause was found to be a "human error" in the manual transfer of the batch number during the root cause analysis.
5 min. reading time | by Rainer Gnibl
Some essential differences between EU GMP Guide Part I (GMP for medicinal products) and Part II (GMP for APIs) are:
7 min. reading time | by Ruven Brandes
The integrity of the filter must be checked before and after use. This is a requirement of the EU GMP Guide1 and of the Ph. Eur. 2 The FDA3 also requires the integrity check, focussing on performance after the filter has been used.
5 min. reading time | by Felix Tobias Kern
The differentiation between medical devices and medicinal products is a constant challenge for pharmaceutical manufacturers. Does my product meet the definition of a medical device according to the EU Medical Device Directive (MDD) or the definition of a medicinal product according to EU-Directive 2001/83 for medicinal products?
5 min. reading time | by Christine Oechslein
Any action related to medicinal products must be traceable, because the life and health of humans and animals are at stake.
5 min. reading time | by Richard Denk
When designing facilities there are numerous aspects to consider. These include not only the regulatory and normative requirements but also the functionality and cost effectiveness as well as the principles of hygienic design.
5 min. reading time | by Stephanie Blum
A management review is carried out on a regular basis to check the suitability and effectiveness of the pharmaceutical quality system (PQS). It is one of the most effective PQS tools available.
8 min. reading time | by Dr. Sabine Paris
Experts: GMP inspector Lea Joos, Christian Gausepohl, PhD, QP and Head of Quality Unit
7 min. reading time | by Brian Matye, Jeanne Moldenhauer, Susan Schniepp
9 min. reading time | by Petra Rempe and Martin Mayer
An excerpt from the GMP Compliance Adviser, Chapters 19.A Agency expectations of quality risk management and 19.B Application and benefits of QRM in the pharmaceutical industry
8 min. reading time | by Nadja Schaubhut
A GMP-DIALOGUE of the GMP Conference, the GMP-BERATER Tage, in October 2019 revolved around the topic "Disruptive technologies in the production of pharmaceuticals". The participants asked questions about the topic, which the two experts answered in an exciting discussion.
5 min. reading time | by Doris Borchert
In our company, every step of the production process is documented on the batch processing record, which is printed out on paper beforehand. Prior to this, all batches used were entered in the record by hand. This often resulted in an unclear spelling.
7 min. reading time | by Harald Flechl
Buildings for pharmaceutical production and the therein integrated infrastructure systems have in common that they have to be planned, realised and operated individually and according to the specific case. This individual character results in an increased risk of faults, which must be recognised and rectified in a timely manner so that they do not endanger the quality of the produced medicinal products.
7 min. reading time | by Sabine Rabus
A GMP dialogue of the GMP conference, the GMP BERATER Tage, in October 2019 was entitled "The QP should decide or lessons learned". The participants brought along concrete questions, the experts gave clear answers. A lively exchange developed, during which the participants also reported in detail on their experiences. We have summarised the most important results for you in this protocol.
7 min. reading time | by Sabine Paris
Are you already training online or still offline? What do the employees, the management, the works council and other stakeholders want? How can this be controlled and GMP-compliant? How can blended learning be implemented?
5 min. reading time | by Doris Borchert
Would you have known? Around 90% of all product recalls by pharmaceutical companies are due to errors in printed packaging materials. It is not the quality of the drug per se that calls patient safety into question, but incorrect or faulty information on the packaging.
7 min. reading time | by Doris Borchert
At our GMP conference, the GMP-BERATER Tage in October 2019 the GMP-DIALOGUE on the topic "Technology for the manufacture of medicinal products" took place. Questions on the topic were asked by participants and answered by GMP inspector Rainer Gnibl, PhD and technology-expert Ruven Brandes in a lively discussion.
11 minutes reading time | by Hansjörg Gutmann, Markus Kopf, Markus Salemink, Dr. Christian Sander
Numbers play a key role in the manufacture of medicinal products. From the receipt of the raw materials to the final release of the finished product, results (actual values) are repeatedly compared with specifications (target values) to decide whether the quality meets the requirements. This applies equally to measured values in the manufacturing process and to analytical results in the laboratory.
7 min. reading time | by Dr. Sabine Paris
A GMP DIALOGUE of the GMP Conference, the GMP BERATER Tage, in October 2019 was entitled "Basic GMP questions and answers". Here, the questions could be asked to which the participants always wanted to have an answer. The two experts provided answers in the course of a lively discussion.
15 min. reading time | by Tim Sandle
To assist pharmaceutical manufacturers and distributors to understand the areas where good manufacturing practice (GMP) inspectors have found compliance problems during GMP inspections in the UK and overseas, the UK Medicines and Healthcare Products Regulatory Agency (MHRA) GMP Inspectorate has issued data, during October 2019, relating to common deficiencies from previous GMP inspections conducted during 2018 [1].
5 min. reading time | by André Deister, Sabine Mendel
Pharmaceutical packaging materials have a variety of functions. The main purpose of primary packaging materials, for example, is to protect the medicinal product against the physical effects of light, air and moisture. Secondary packaging materials provide information on the amount, dosage type and application of the packaged medicinal product.
10 min. reading time
As a LOGFILE subscriber you are already familiar with our "Question of the week".
7 min. reading time | by Doris Borchert
At our GMP Conference, the “GMP-BERATER Tage“, in October 2019 we presented a GMP dialogue on "Microbiological Monitoring in non-sterile areas". Questions on the topic were asked by participants and answered by GMP inspector Franz Schönfeld, PhD and microbiologist Frank Mertens, PhD in a lively discussion.
7 min. reading time | by Lea Joos and Doris Borchert
Mrs. Joos, you put in your new chapter "GDP inspections: Frequent deficiencies and how to avoid them" the 10 most common deficiencies in the qualification of logistics service providers. In your opinion, where are the biggest deficits?
7 min. reading time
"We have an active pharmaceutical ingredient (ICH Q7) in our GMP warehouse which may be stored up to max. 40°C according to the stability data available. This is the suspension of a UV filter. Now the existing monitoring system is to be replaced.
5 min. reading time | by Martin Mayer
An excerpt from the GMP Series e-book Failure Management in a GMP Regulated Environment
9 min. reading time | by Doris Borchert
Ventilation units are the heart of cleanrooms. They enable the air to circulate in the same way as the heart enables the blood to do so in the human body.
6 min. reading time | by Thomas Peither
The PDA/FDA Joint Regulatory Conference in September in Washington, DC, was once again an important meeting place for the pharmaceutical industry this year. Topics ranged from regulatory updates, quality aspects, compliance challenges, new technologies for manufacturing, laboratory and quality assurance to control strategies, facility life cycles, inspection strategies and audit effectiveness.
4 min. reading time | by Frank Böttcher
An excerpt from the e-book Managing Contract Manufacturers and Testing Labs and the online knowledge portal GMP Compliance Adviser
6 minutes reading time | by Felix Tobias Kern
The legislation's demand on the pharmaceutical industry for an integrated risk approach (e.g. according to ICH Q9) implies major challenges in terms of effort and costs.
10 minutes reading time | by Sabine Paris
Pharmaceutical manufacturers regularly have to implement new regulatory requirements. The EMA, for example, requires the setting of health based exposure limits (PDE values) for all medicinal products manufactured in shared facilities.
6 min. reading time | by Rainer Gnibl
The actual batch release procedure for finished products can be subdivided into three steps. These build up on each other and should be carried out chronologically.
7 min. reading time | by Harald Flechl and Dr Doris Borchert (editorial editing)
In clean rooms, it is necessary to create a clear demarcation to adjacent, less clean areas. Since the beginning of clean room technology, airlocks have established themselves as an effective means of separating rooms.
4 min. reading time | by Sabine Rabus
In our company it is planned to write all documents in English. However, many employees do not speak English. Is there a rule that says that the documents must be "readable and understandable" for employees?
10 min. reading time | by Tim Sandle
In recent years, there has been an increase in international drug inspections to assure that good manufacturing practice (GMP) is being appropriately applied no matter where a bulk pharmaceutical chemical or active pharmaceutical ingredient (API) is made. With the regulation and inspection of API manufacturers falling under agencies operating in the European Economic Area, there has been little (until now) trend data relating to facility inspections.
5 min. reading time | by Christoph Frick and Nicola Spiggelkötter
Passive shipping containers are characterized by the insulation material used and the cooling media. Both components then determine the running time, which can be between 24 and 120 hours. Simple cooling boxes are made of polystyrene, high-end versions feature vacuum panels.
3 min. reading time | by Markus Limberger
An important aspect of dealing with substances in a laboratory is the administration and control of the substances. It is important that the substances are only used as intended and before their shelf life expires.
12 min. reading time | by Sabine Rabus
The transport of pharmaceuticals is subject to strict requirements. This reality has long since arrived in logistics. Transparency, reliability and compliance with rules are therefore part of the daily business of a pharmaceutical logistics company.
6 min. reading time | by Christine Oechslein
If somebody kept their shoes in a china cupboard or prepared a cream cake in the bathroom (directly beside the hairbrush and razor), most people would find it unhygienic. We are used to our living room and other rooms being used for particular activities.
8 min. reading time | by Christine Oechslein
In Part I, Paragraph 2.11 of the EU GMP Guidelines, it is required that "approved training programmes should be available" in GMP-liable establishments.
10 min. reading time | by Thomas Peither
What an exceptional conference! From June 25th-26th, 2019, the PDA Europe Annual Meeting in Amsterdam was again a meeting that demonstrated the current view on important topics in the pharmaceutical business. The first part of the conference summary covers the plenary session in the morning of the first conference day.
4 min. reading time | by Markus Veit
Pharmacopoeias play an important role in quality control. They define important standards and framework conditions for tests; they contain requirements for reagents and reference materials as well as specifications for active substances (APIs), excipients, packaging materials and medicinal products. In addition, pharmacopoeias also contain descriptions of all relevant test methods.
4 min. reading time | by Christian Gausepohl and Jürgen Ortlepp
"Receiving and dispatch bays should protect materials and products from the weather.
8 min. reading time | by Sabine Paris
At the GMP BERATER Days in October 2018, the GMP Dialogue on "Management of GMP Projects and New Factory Buildings" took place. Questions about the topic were asked by the participants and answered by the experts Dr Helmut Bender, Boehringer Ingelheim, and GMP inspector Dr Daniel Müller and in a lively discussion.
5 min. reading time
With this e-learning course you can get familiar with the topic of Good Distribution Practice (GDP)! The aim is to explain the GDP-Regulation principles in a quick and sufficient way.
5 min. reading time | by Frank Boettcher
Apart from the statutory requirements that must be observed, commercial aspects and corporate policy also have a role to play when selecting a contract laboratory.
4 min. reading time | by Stephanie Blum
Every patient who is ill and takes a medicinal product hopes it is effective and heals the illness or at least alleviates the symptoms.
6 min. reading time | by Sabine Paris
The European Annual Conference of the International Society of Pharmaceutical Engineering (ISPE) attracted over 700 participants to Dublin from 1st to 3rd April 2019. The main topic was “Drive and Leverage Innovation for Pharma”.
5 min. reading time | by Sabine Paris
Are you already training online or still offline? What do the employees, the management, the works council and other stakeholders want? How can this be controlled and GMP-compliant? How can blended learning be implemented?
6 min. reading time | by Doris Borchert
Would you have known? Around 90% of all product recalls by pharmaceutical companies are due to errors in printed packaging materials. It is not the quality of the drug itself that calls into question patient safety, but incorrect or erroneous information on the packaging. A comma on our bank statements can bring tears to our eyes or a smile on our lips.
7 min. reading time | by Sabine Paris
The European Annual Conference of the International Society of Pharmaceutical Engineering (ISPE) attracted over 700 participants to Dublin from 1st to 3rd April 2019. The main topic was “Drive and Leverage Innovation for Pharma”. The Executive Forum focused on the industrial digitisation as a key enabler to drive innovation. Driving continuous improvement in a digital age needs a number of pre-requisites and face new challenges and opportunities.
9 min. reading time | by Paulino Alonso
The ICH Q3D Guideline for Elemental Impurities came into effect on January 2018 for all the products for human use. To date, most of the companies have finished the implementation (maybe not at 100%, but ongoing) and now, the challenge is to keep the reports updated.
5 min. reading time | by Ulrike Reuter
A risk analysis is a fundamental element of a qualification because the content and extent of the qualification tasks are determined therein.
7 min. reading time |
Despite much discussion about the subject over the past three years in particular, data integrity issues remain a common feature on 483 letters issued by the U.S. Food and Drug Administration and data handling matters are also a focus of enforcement actions (as well as inspection findings from other regulatory agencies).
5 min. reading time | by Josef Künzle
The calibration of analytical instruments is stipulated in the GMP Guidelines.
8 min. reading time | by Doris Borchert
There are no regulatory requirements for the definition of air quality and its monitoring in non-sterile production areas. The topic was discussed by our team of experts and in some cases very different answers were received. The different points of view made us curious - how is this question solved in pharmaceutical practice?
5 min. reading time | by Fritz Röder
As in the case of all qualifications, the risk analysis is carried out to consolidate the knowledge of all the parties involved and define the necessary test and action points required for the qualification. This is an extremely time-consuming process.
4 min. reading time | by Christine Oechslein
E-learning can be seen as didactically meaningful support in the learning process. More and more people prefer to use their PCs and the internet instead of attending seminars or reading documents. The younger generation in particular, who grew up with computers, can absorb a lot of learning content better and faster through e-learning, or can already work out familiar contents in addition.
4 min. reading time | by Harald Flechl
A cost-optimized approach to project planning and execution, including the use of BIM (Building Information Modelling), will be used increasingly in the future. If this technology is applied correctly and over the entire project sequence, it makes it possible to optimise the planning, execution and usage of buildings, furnishings and installations using digitally prepared product data and software.
8 min. reading time | by Dr. Sabine Paris
The new Annex 1 of the EU GMP Guide is to be finalised in December 2018. The publication is planned for spring 2019. Which changes will surely come, where is there still a need for discussion? Where are your ambiguities?
9 min. reading time | by Sabine Rabus
This summary review of GMP documents published in 2018 provides an overview on developments in important international legislation and regulations.
5 min. reading time | by Hanfried Seyfarth
Actions to be taken when levels are exceeded and the related responsibilities should be described in detail in a separate SOP. The Monitoring SOP should include a reference to this SOP.
5 min. reading time | by Michael Hiob
The qualification of equipment and machinery is performed throughout its lifecycle (see Figure 1).
4 min. reading time | by Christian Gausepohl
Certain questions and challenges keep recurring during product transfers. It is important to anticipate them systematically and put appropriate preventive measures in place. The critical issues include:
5 min. reading time | by Thilo Gukelberger
An EDMS is typically used to store the following information units:
5 min. reading time | by Jens Hrach
Requirements for the establishment of limit values first appeared in the FDA Guide to Inspections of Validation of Cleaning Processes in 1993:
9 min. reading time | by Doris Borchert
Ventilation units are the heart of cleanrooms. They enable the air to circulate in the same way as the heart enables the blood to do so in the human body.
6 min. reading time | by Rainer Gnibl
The actual batch release procedure for finished products can be subdivided into three steps. These build up on each other and should be carried out chronologically.
6 min. reading time | by Mark Crawford
The pharmaceutical supply chain is becoming an increasingly complex system, making it harder for drug manufacturers and their partners to ensure safe and timely delivery. Keeping track of products is not always a transparent process.
6 min. reading time | by Christoph Frick
There is no legal, ecological or pharmaceutical reason why a preparation should be heated from 12 °C (the outside temperature), for example, to a constant temperature of 20 °C (i.e. the mean of 15–25 °C) and stored at this temperature.
6 min. reading time | by Susanne Sailer
Quality Oversight and Lean QA – two terms that have been making the rounds for years:
6 min. reading time | by Thomas Peither
Outstanding! This is my one-word summary for the PDA European Annual Meeting 2018. The second plenary session focused on regulatory progress and the discussion gave some insights into upcoming topics.
5 min. reading time | by Fritz Röder
As in the case of all qualifications, the risk analysis is carried out to consolidate the knowledge of all the parties involved and define the necessary test and action points required for the qualification.
12 min. reading time | by Fritz Röder
The new draft of Annex 1 of the EU GMP Guidelines keeps numerous responsible persons in the pharmaceutical industry busy. Are you already prepared for the possible changes?
14 min. reading time | by Gary Bird
Data integrity has become the most recent inspectional “buzz word” in the pharmaceutical industry. Over the last 6 to 8 years, the focus on data reliability has hit an all-time high with regulatory authorities across the globe. This has resulted in numerous regulatory actions.
6 min. reading time | by Ruven Brandes
When performing sterile filtration of a solution, it is recommended that a SOP describing all required components of the equipment and accessories should be used in order to ensure that no steps are omitted.
6 min. reading time | by Thomas Peither
Outstanding! This is my one-word summary for the PDA European Annual Meeting 2018. In this first article you will read about the plenary session on Pharmaceutical Industry Highlights - Past, Present, Future, and get snapshots of topics presented on 26 and 27 June in Berlin.
6 minutes reading time | by Michael Hiob
Cleaning processes should remove residues from surfaces that come in contact with the product to prevent the cross-contamination of subsequent products.
10 min. reading time | by Andrew Love
Following approval in March 2017 by the European Council and in April 2017 by the European Parliament, the Medical Devices Regulation (MDR) – Regulation (EU) 2017/745 – and In Vitro Diagnostic Medical Devices Regulation (IVDR) – Regulation (EU) 2017/746 – were published in the Official Journal of the European Union on 5 May 2017 [1,2].
6 min. reading time | by Thomas Peither, Ulrike Reuter, Rainer Röcker
During a Performance Qualification (PQ) the proper interaction of the previously tested units of a complete equipment line or plant is tested, such as for an HVAC system, a purified water plant and filling or packaging lines.
8 min. reading time | by Thomas Peither
When it comes to data integrity: What are the current regulatory expectations? How do you ensure the reliability of your suppliers? Do you understand the impact of culture on your organisation?
7 min. readingtime | by Dr. Markus Limberger
The main objective of the pharmaceutical industry when manufacturing and testing active ingredients, excipients and proprietary medicinal products is to guarantee the quality and safety of the product and thus the safety of the patient.
6 minutes reading time
by Harald Flechl
6 minutes reading time
by Susanne Sailer
8 minutes reading time
by Thomas Peither
8 minutes reading time
by Thomas Peither
6 minutes reading time
by Michael Hiob, PhD
6 minutes reading time
by Sabine Rabus and Christine Gräßlin
6 minutes reading time
by Walid El Azab
4 minutes reading time
by Sabine Rabus and Christine Gräßli
8 minutes reading time
by Richard Denk
6 minutes reading time
by Hanfried Seyfarth, PhD
6 minutes reading time
A commentary by Ruven Brandes and Fritz Röder
6 minutes reading time
by Walid El Azab
6 minutes reading time
A commentary by Ruven Brandes and Fritz Röder
5 minutes reading time
by Markus Veit, PhD
6 minutes reading time
by Andrew Love and Stephen McIndoe
6 minutes reading time
by Andrew Love and Stephen McIndoe
5 minutes reading time
by Ulrike Reuter
8 minutes reading time
by Martin Mayer
7 minutes reading time
by Sabine Rabus
5 minutes reading time
by Richard Denk
8 minutes reading time
by Beatriz Carrero, PhD, Azierta and Sabine Paris, PhD, Maas & Peither – GMP Publishing
5 minutes reading time
by Fritz Röder
By Dr. Christian Gausepohl
5 minutes reading time
by Josef Künzle, PhD, Wolfgang Nedvidek, PhD
7 minutes reading time
by Sabine Rabus
by Fritz Röder
4 minutes reading time
by Christian Gausepohl, PhD
by Dr. Tim Sandle
by Dr. Hans H. Schicht
6 minutes reading time
by Dr. Tim Sandle
5 minutes reading time
by Christian Gausepohl, PhD
7 minutes reading time
by Sabine Paris, PhD
7 minutes reading time
by Sabine Paris, PhD
by Michael Hiob, PhD
by Sabine Paris, PhD
by Sabine Paris, PhD
by Hans H. Schicht, PhD
6 minutes reading time
by Sabine Paris, PhD
by Dr. Rainer Gnibl
by Thomas Peither
by Fritz Röder
by Dr. Christine Oechslein
We have prepared for you page 1 and 3 of the document. Please click on the following link to read the excerpt.
by Dr. Christine Oechslein
We have prepared for you page 1 and 3 of the document. Please click on the following link to read the excerpt.
by Dr. Christine Oechslein
3 min. reading time
by Rainer Gnibl
6 minutes reading time
by Sabine Paris, PhD
4 min. reading time
by Stefan Kettelhoit, PhD
by Dr. Christine Oechslein
(reading time 5 min)
by Fritz Röder and Ruven Brandes
3 min. reading time
by Dr. Bernd Renger
(5 min. reading time)
by Dr. Sabine Paris
by Sabine Rabus
(4 min. reading time)
by Thomas Peither
(3 min. reading time)
by Dr. Margit Gieseler
by Ruven Brandes
by Dr. Hanfried Seyfarth
An excerpt from the GMP MANUAL
by Dr. Frank Böttcher and Dr. jur. Ingo Schneider
3 min. reading time
by Cornelia Wawretschek
by Dr. Sabine Paris
(5 min. reading time)
by Dr. Sabine Paris
by Fritz Röder
5 min. reading time |
From the start of the project to the release of the technical design: Risk analysis is a constant companion.
Risk analyses can or must be carried out at different points in time within the process of procurement and qualification. Here is a brief outline of the phases of risk analyses in project implementation.
7 min. reading time | by Felix Kern, PhD and Liwa Schneider
Deviation management plays an increasingly important role in the collection and review of KPIs (Key Performance Indicators) for pharmaceutical production and quality processes. Tracking the cause of deviations in particular provides information on how stable the respective processes are, where there are gaps and where countermeasures need to be taken with corrective and preventive actions (CAPAs).
8 min. reading time | by Sabine Paris, PhD
"Contaminants in medicinal products – focus on nitrosamines" was the title of an online training course organised by the German FORUM Institute on 12 November 2021. Four renowned experts from the authorities, industry and consulting shed light on all aspects of nitrosamines that play a role in the life cycle of a medicinal product:
7 min. reading time | by Doris Borchert, PhD
The 27th PTS GMP Conference took place face-to-face and in parallel digitally from 30.11. to 01.12.2021 in Mainz, Germany. The hybrid event was broadcast live from the Atrium Hotel in Mainz, where most of the speakers were present in person.
The presentation by Rico Schulze, Saxon State Ministry for Social Affairs and Social Cohesion, on the revision status and publication of Annex 1 to the EU GMP Guideline was particularly eagerly awaited.
8 min. reading time |
The life cycle of an equipment begins with initial qualification and ends with decommissioning. Once a qualification status has been achieved, it must be guaranteed over the entire life cycle until the equipment is decommissioned. This is ensured by regular calibration, maintenance, effective change management and periodic review.
7 min. reading time | by Stephanie Blum, PhD
If a new service or material is required, the competent department first checks whether this service or material can be obtained from an already qualified supplier. If this is the case, the department initiates a follow-up qualification. Otherwise, the identification and pre-selection of potential new suppliers is carried out by the department itself.
8 min. reading time | by Simone Ferrante
In Europe, companies with a wholesale distribution authorisation, the management must appoint a responsible person who is responsible for the introduction and implementation of a quality management system and compliance with the GDP rules.
5 min. reading time | by Felix Tobias Kern, PhD and Liwa Schneider
The GMP-compliant and timely management of deviations is very often addressed in audits. One reason for this is that deviations reveal gaps in the defined quality systems or indicate that they have not been set up correctly.
6 min. reading time | by Sabine Paris, PhD
The PDA/FDA Joint Regulatory Conference, which is now in its 30th year, took place as a virtual event from September 27 – September 29. The Conference focused on the role of effective quality systems in ensuring an ongoing state of control throughout the product lifecycle by vigilantly managing risks to manufacturing and quality.
7 min. reading time | by Sabine Paris, PhD
The PDA/FDA Joint Regulatory Conference, which is now in its 30th year, took place as a virtual event from September 27 – September 29. The Conference focused on the role of effective quality systems in ensuring an ongoing state of control throughout the product lifecycle by vigilantly managing risks to manufacturing and quality.
12 min. reading time | by Harald Flechl
We operate a laminar flow above an injection moulding machine in a cleanroom, GMP Grade C (ISO 8 in operation, ISO 7/at rest). The laminar flow achieves ISO class 5 within the cleanroom area.
7 min. reading time | by Heike Meichsner, Olaf Mundszinger, PhD, Susanne Schweizer
The registration batches correspond as nearly as possible to the later commercial batches in the marketing phase with regard to the equipment, starting materials and manufacturing processes used.
8 min. reading time | by Richard Denk
Isolators are used in the handling of toxic and highly potent substances and in the production of sterile products.
9 min. reading time | by Thomas Peither
The inspection is carried out in the front office and prepared in the back office. The preparation room is used to train and instruct staff.
9 min. reading time | by Dennis Sandkühler
On the basis of the process-related requirements set out in the specifications, ISPE GAMP® 5 provides for a process risk analysis to identify risks relating to patient safety, product quality, data integrity and compliance requirements.
7 min. reading time | by Stephanie Blum
With this e-learning course you can get familiar with the topic of Good Distribution Practice (GDP)!
7 min. reading time | by Harald Flechl
The design qualification process may vary depending on the project and the client's requirements and may be carried out in two or three design phases.
15 min. reading time | by Ulrich Kissel and David Cockburn
Social distancing posed an interesting question for the Qualified Person (QP) in the early days of the COVID-19 pandemic:
8 min. reading time | by Thomas Peither
Were you able to follow the PDA Annual Meeting of the Parenteral Drug Association this year? Or were you like many others who spent the whole day with web meetings and have no time or mood for more online conferences?
The time has come, the curtain goes up! Now your brand-new online journal is launched.
Let the newly designed GMP:Blog support you in the work with GMP.
8 min. reading time | by Sabine Paris
In 2015, with the revision of Chapters 3 and 5 and Annex 15 of the EU GMP Guide and with the publication of the EMA PDE Guideline a paradigm shift took place in establishing limit values for the validation of cleaning processes.
5 min. reading time | by Markus Veit
This chapter deals with the practical aspects of implementing the European requirements for data integrity.
8 min. reading time | by Harald Flechl
Over the past several years, wall and ceiling systems have become the established state of the art in finishing technology. The numerous manufacturers of such systems also offer solutions that are suitable for fire zones and large, high rooms – such as warehouse storage rooms.
10 min. reading time | by Doris Borchert and Christian Gausepohl
To err is human - and is only too willingly used as the most probable cause for deviations of all kinds. It is also temptingly easy to look for the cause of error in individual (mis)behaviour.
10 min. reading time
Every week we publish GMP related questions which you might have asked yourself before. You get short and precise answers, links and working material to the corresponding chapters in the GMP Compliance Adviser.
10 min. reading time | by Richard Denk
The literal meaning of containment is “holding together” or in its common sense “limiting expansion”. In the active ingredient, pharmaceutical and biopharmaceutical industries it is understood to mean the enclosure of a production process or a dangerous location.
6 min. reading time | by Rainer Gnibl
Excerpt from the GMP Compliance Adviser Chapter 14.J and the GMP Series e-book EU-Compliant Batch Release of Medicinal Products
3 min. reading time
Is there a normative source for the fact that the reviewer of a document cannot be the same person who prepared it?
6 min. reading time | by Christoph Frick
There is no legal, ecological or pharmaceutical reason why a preparation should be heated from 12 °C (the outside temperature), for example, to a constant temperature of 20 °C (i.e. the mean of 15–25 °C) and stored at this temperature.
8 min. reading time | by Hedley Rees
Not for the first time, pharma supply-chains have become the subject of global debate among key stakeholders, but for the wrong reasons.
8 min. reading time | by Christine Oechslein
In Part I, Paragraph 2.11 of the EU GMP Guidelines, it is required that "approved training programmes should be available" in GMP-liable establishments.
5 min. reading time | by Crystal Booth
When selecting the number of sites to be sampled, the author recommends utilizing established guidelines. For example, ISO 14644-1:2015 contains a table used to establish the number of nonviable (total) particulate samples required based on the size of the room to be monitored.
5 min. reading time | by Lea Joos
In the case of the deviation inspected, it was found that the batch number, which had to be manually transferred to the product before production started, was not correctly transferred to the product. The cause was found to be a "human error" in the manual transfer of the batch number during the root cause analysis.
5 min. reading time | by Rainer Gnibl
Some essential differences between EU GMP Guide Part I (GMP for medicinal products) and Part II (GMP for APIs) are:
5 min. reading time | by Felix Tobias Kern
The differentiation between medical devices and medicinal products is a constant challenge for pharmaceutical manufacturers. Does my product meet the definition of a medical device according to the EU Medical Device Directive (MDD) or the definition of a medicinal product according to EU-Directive 2001/83 for medicinal products?
5 min. reading time | by Christine Oechslein
Any action related to medicinal products must be traceable, because the life and health of humans and animals are at stake.
8 min. reading time | by Dr. Sabine Paris
Experts: GMP inspector Lea Joos, Christian Gausepohl, PhD, QP and Head of Quality Unit
9 min. reading time | by Petra Rempe and Martin Mayer
An excerpt from the GMP Compliance Adviser, Chapters 19.A Agency expectations of quality risk management and 19.B Application and benefits of QRM in the pharmaceutical industry
5 min. reading time | by Doris Borchert
In our company, every step of the production process is documented on the batch processing record, which is printed out on paper beforehand. Prior to this, all batches used were entered in the record by hand. This often resulted in an unclear spelling.
7 min. reading time | by Sabine Rabus
A GMP dialogue of the GMP conference, the GMP BERATER Tage, in October 2019 was entitled "The QP should decide or lessons learned". The participants brought along concrete questions, the experts gave clear answers. A lively exchange developed, during which the participants also reported in detail on their experiences. We have summarised the most important results for you in this protocol.
5 min. reading time | by Doris Borchert
Would you have known? Around 90% of all product recalls by pharmaceutical companies are due to errors in printed packaging materials. It is not the quality of the drug per se that calls patient safety into question, but incorrect or faulty information on the packaging.
11 minutes reading time | by Hansjörg Gutmann, Markus Kopf, Markus Salemink, Dr. Christian Sander
Numbers play a key role in the manufacture of medicinal products. From the receipt of the raw materials to the final release of the finished product, results (actual values) are repeatedly compared with specifications (target values) to decide whether the quality meets the requirements. This applies equally to measured values in the manufacturing process and to analytical results in the laboratory.
7 min. reading time | by Dr. Sabine Paris
A GMP DIALOGUE of the GMP Conference, the GMP BERATER Tage, in October 2019 was entitled "Basic GMP questions and answers". Here, the questions could be asked to which the participants always wanted to have an answer. The two experts provided answers in the course of a lively discussion.
5 min. reading time | by André Deister, Sabine Mendel
Pharmaceutical packaging materials have a variety of functions. The main purpose of primary packaging materials, for example, is to protect the medicinal product against the physical effects of light, air and moisture. Secondary packaging materials provide information on the amount, dosage type and application of the packaged medicinal product.
7 min. reading time | by Doris Borchert
At our GMP Conference, the “GMP-BERATER Tage“, in October 2019 we presented a GMP dialogue on "Microbiological Monitoring in non-sterile areas". Questions on the topic were asked by participants and answered by GMP inspector Franz Schönfeld, PhD and microbiologist Frank Mertens, PhD in a lively discussion.
7 min. reading time | by Lea Joos and Doris Borchert
Mrs. Joos, you put in your new chapter "GDP inspections: Frequent deficiencies and how to avoid them" the 10 most common deficiencies in the qualification of logistics service providers. In your opinion, where are the biggest deficits?
5 min. reading time | by Martin Mayer
An excerpt from the GMP Series e-book Failure Management in a GMP Regulated Environment
6 min. reading time | by Thomas Peither
The PDA/FDA Joint Regulatory Conference in September in Washington, DC, was once again an important meeting place for the pharmaceutical industry this year. Topics ranged from regulatory updates, quality aspects, compliance challenges, new technologies for manufacturing, laboratory and quality assurance to control strategies, facility life cycles, inspection strategies and audit effectiveness.
6 minutes reading time | by Felix Tobias Kern
The legislation's demand on the pharmaceutical industry for an integrated risk approach (e.g. according to ICH Q9) implies major challenges in terms of effort and costs.
6 min. reading time | by Rainer Gnibl
The actual batch release procedure for finished products can be subdivided into three steps. These build up on each other and should be carried out chronologically.
4 min. reading time | by Sabine Rabus
In our company it is planned to write all documents in English. However, many employees do not speak English. Is there a rule that says that the documents must be "readable and understandable" for employees?
5 min. reading time | by Christoph Frick and Nicola Spiggelkötter
Passive shipping containers are characterized by the insulation material used and the cooling media. Both components then determine the running time, which can be between 24 and 120 hours. Simple cooling boxes are made of polystyrene, high-end versions feature vacuum panels.
12 min. reading time | by Sabine Rabus
The transport of pharmaceuticals is subject to strict requirements. This reality has long since arrived in logistics. Transparency, reliability and compliance with rules are therefore part of the daily business of a pharmaceutical logistics company.
10 min. reading time | by Thomas Peither
What an exceptional conference! From June 25th-26th, 2019, the PDA Europe Annual Meeting in Amsterdam was again a meeting that demonstrated the current view on important topics in the pharmaceutical business. The first part of the conference summary covers the plenary session in the morning of the first conference day.
4 min. reading time | by Christian Gausepohl and Jürgen Ortlepp
"Receiving and dispatch bays should protect materials and products from the weather.
5 min. reading time
With this e-learning course you can get familiar with the topic of Good Distribution Practice (GDP)! The aim is to explain the GDP-Regulation principles in a quick and sufficient way.
4 min. reading time | by Stephanie Blum
Every patient who is ill and takes a medicinal product hopes it is effective and heals the illness or at least alleviates the symptoms.
5 min. reading time | by Sabine Paris
Are you already training online or still offline? What do the employees, the management, the works council and other stakeholders want? How can this be controlled and GMP-compliant? How can blended learning be implemented?
7 min. reading time | by Sabine Paris
The European Annual Conference of the International Society of Pharmaceutical Engineering (ISPE) attracted over 700 participants to Dublin from 1st to 3rd April 2019. The main topic was “Drive and Leverage Innovation for Pharma”. The Executive Forum focused on the industrial digitisation as a key enabler to drive innovation. Driving continuous improvement in a digital age needs a number of pre-requisites and face new challenges and opportunities.
5 min. reading time | by Ulrike Reuter
A risk analysis is a fundamental element of a qualification because the content and extent of the qualification tasks are determined therein.
5 min. reading time | by Josef Künzle
The calibration of analytical instruments is stipulated in the GMP Guidelines.
5 min. reading time | by Fritz Röder
As in the case of all qualifications, the risk analysis is carried out to consolidate the knowledge of all the parties involved and define the necessary test and action points required for the qualification. This is an extremely time-consuming process.
4 min. reading time | by Harald Flechl
A cost-optimized approach to project planning and execution, including the use of BIM (Building Information Modelling), will be used increasingly in the future. If this technology is applied correctly and over the entire project sequence, it makes it possible to optimise the planning, execution and usage of buildings, furnishings and installations using digitally prepared product data and software.
9 min. reading time | by Sabine Rabus
This summary review of GMP documents published in 2018 provides an overview on developments in important international legislation and regulations.
5 min. reading time | by Hanfried Seyfarth
Actions to be taken when levels are exceeded and the related responsibilities should be described in detail in a separate SOP. The Monitoring SOP should include a reference to this SOP.
4 min. reading time | by Christian Gausepohl
Certain questions and challenges keep recurring during product transfers. It is important to anticipate them systematically and put appropriate preventive measures in place. The critical issues include:
5 min. reading time | by Jens Hrach
Requirements for the establishment of limit values first appeared in the FDA Guide to Inspections of Validation of Cleaning Processes in 1993:
9 min. reading time | by Doris Borchert
Ventilation units are the heart of cleanrooms. They enable the air to circulate in the same way as the heart enables the blood to do so in the human body.
6 min. reading time | by Mark Crawford
The pharmaceutical supply chain is becoming an increasingly complex system, making it harder for drug manufacturers and their partners to ensure safe and timely delivery. Keeping track of products is not always a transparent process.
5 min. reading time | by Fritz Röder
As in the case of all qualifications, the risk analysis is carried out to consolidate the knowledge of all the parties involved and define the necessary test and action points required for the qualification.
